Clinical Trials Logo

Clinical Trial Summary


The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland. Researchers believe a new drug called CUDC-907 may be able to help people with thyroid cancer that has spread or has gotten worse.


To see if CUDC-907 will shrink tumors in people with advanced thyroid cancer.


People at least 18 years old who have been diagnosed with locally advanced and metastatic thyroid cancer.


Participants will be screened with:

Medical history

Physical exam

Blood and urine tests

Electrocardiogram (ECG) heart test.

Review of their symptoms and how they perform normal activities

A scan will be performed. Some will have a computed tomographic scan (CT) that takes pictures of the body using a small amount of radiation. Some will have magnetic resonance imaging (MRI) that uses a magnetic field to take pictures.

Bone scan (some participants)

Fludeoxyglucose (FDG) positron emission tomography (PET) scan to produce a tumor image.

A sample of their tumor from a previous surgery. They may have a biopsy of their tumor if a tumor sample is not available from a previous surgery.

Participants will be given CUDC-907 in tablet form. They will take it by mouth once a day for 5 days, then take 2 days off, each week.

While taking the study drug, participants will have study visits that repeat the screening tests.

After they stop treatment, participants will have 3 follow-up visits over a year. They will repeat some tests. Then participants will be contacted by phone or e-mail every 6 months....

Clinical Trial Description


- There are no standard or effective systemic therapies for metastatic or locally advanced poorly differentiated and undifferentiated thyroid cancer.

- Poorly differentiated and undifferentiated thyroid cancer are aggressive, with high mortality.

- CUDC-907 is a first-in-class dual inhibitor of histone deacetylase (HDAC) and PI3K signaling.

- Approximately 80% of poorly differentiated and undifferentiated thyroid cancers have driver mutations in the PI3K/AKT pathway or activation of the pathway.

- HDAC2 is upregulated in poorly differentiated and undifferentiated thyroid cancer, and aggressive variants of differentiated thyroid cancer, and CUDC-907 treatment reduces HDAC2 levels in thyroid cancer cells.

- CUDC-907 inhibits thyroid cancer cell growth, invasion and migration in vitro.

- In addition to inhibiting the PI3K/AKT signaling pathway, CUDC-907 inhibits the EGFR/RAS/RAF/MEK/ERK signaling pathway, which is also activated in poorly differentiated and undifferentiated thyroid cancer.

- CUDC-907 inhibits growth and metastases in a mouse model of metastatic thyroid cancer.

- We hypothesize that CUDC-907 will cause cancer regression in patients with metastatic and locally advanced poorly differentiated and undifferentiated thyroid cancer, and aggressive variants of differentiated thyroid cancer.


-To determine response to CUDC-907 treatment by Response Evaluation Criteria in Solid Tumors (RECIST) criteria in patients with locally advanced and metastatic poorly differentiated and undifferentiated thyroid cancer, and aggressive variants of differentiated thyroid cancer.


- Age greater than or equal to 18 years

- Thyroid cancer that is refractory to or relapsed after standard treatment.

- Aggressive thyroid cancer confirmed on histology or cytologic analysis.

- Measurable disease.

- Last dose of chemotherapy or last radiotherapy treatment more than 4 weeks prior to starting treatment with this protocol, except for subjects with anaplastic/undifferentiated thyroid cancer who may enroll immediately after discontinuation of previous therapy.


- Open label, phase II trial to determine response to CUDC-907 treatment.

- Patients will be given 60 mg of CUDC-907 orally for 5 consecutive days followed by 2 days off (5/2 schedule).

- One cycle is 21 days. Patients may continue on treatment if there is no disease progression.

- Initial anatomic and functional imaging will be performed at enrollment and after 2 cycles of treatment. Thereafter, anatomic imaging will be performed every two cycles of treatment. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03002623
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Status Terminated
Phase Phase 2
Start date December 22, 2016
Completion date February 12, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00537095 - Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer Phase 2
Recruiting NCT04139096 - Genetic Susceptibility to Radiation Induced Thyroid Cancer
Completed NCT00754182 - Subcuticular Suture Versus Synthetic Glue in Thyroidectomy Incision N/A
Completed NCT00094055 - Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Phase 2
Completed NCT00148213 - Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma N/A
Recruiting NCT01005654 - Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Completed NCT01437254 - To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer Phase 1
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Completed NCT00984282 - Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Phase 3
Completed NCT01292044 - The Role of Elastography in the Diagnosis of Thyroid Nodules N/A
Active, not recruiting NCT02418247 - Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer Phase 2/Phase 3
Completed NCT00467506 - Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma Phase 2
Completed NCT02430714 - Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Recruiting NCT04396912 - Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Recruiting NCT04410601 - Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT N/A
Completed NCT03469310 - Minimizing Narcotic Analgesics After Endocrine Surgery Phase 4
Completed NCT03871387 - The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change N/A
Terminated NCT01838642 - Ponatinib for Advanced Medullary Thyroid Cancer Phase 2
Completed NCT01089335 - Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia